[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630413":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":7,"enrollmentInfo":57,"targetDuration":7,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Institute of Tropical Medicine, Belgium","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Eleni Ayele","LRTC University of Gondar","PRINCIPAL_INVESTIGATOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Nicole Berens-Riha","CONTACT","0460850115","nberens@itg.be",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Johan van Griensven","jvangriensven@itg.be",[23],{"facility":24,"status":25,"city":26,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"University of Gondar","RECRUITING","Gonder","Ethiopia","ET",{"type":30,"coordinates":31},"Point",[32,33],37.46667,12.6,{"lat":33,"lon":32},[36,38],{"name":10,"role":16,"phone":7,"phoneExt":7,"email":37},"eleniayele2@gmail.com",{"name":39,"role":16,"phone":7,"phoneExt":7,"email":40},"Mezgebu Asres","msilamsaw@gmail.com",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[44,46],{"name":45,"class":6},"Armauer Hansen Research Institute, Ethiopia",{"name":24,"class":6},"100630413","recurrent-visceral-leishmaniasis-in-hiv-co-infection-100630413",false,"NCT07487350","Recurrent Visceral Leishmaniasis in HIV Co-Infection","New And Recurrent Visceral Leishmaniasis in HIV Co-Infected Ethiopian Patients: a Cohort Study","ALIVE","Inclusion Criteria:\n\n1. VL-HIV infection 1.1. VL: microscopically confirmed parasite presence in spleen or bone marrow tissue at first episode or relapse; for known active chronic cases: decision to treat VL 1.2. HIV: confirmed viral infection (new or past)\n2. ≥18 years\n\nExclusion Criteria:\n\n1. Not willing to provide written informed consent\n2. Not willing to adhere to the follow-up visits\n3. Mentally or physically incapable to participate in the study (to the discretion of the treating physician)","ALL","18 Years",{"count":58,"type":59},20,"ESTIMATED","OBSERVATIONAL","The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target group in Ethiopia",[63,64],"Hiv","Visceral Leishmaniasis",[66,67,68,69],"HIV","VL","VL Relapse","Immune exhaustion","2026-03-17",{"date":72,"type":73},"2026-03-23","ACTUAL",{"date":75,"type":73},"2025-10-21",{"date":77,"type":59},"2027-12",{"name":5,"class":6},1]